VTYX Company Profile and Key Details

Q: Who are the executives of VTYX?

Dr. John M. Nuss Ph.D.Chief Scientific OfficerProf. William J. Sandborn M.D., Ph.D.Pres & Chief Medical OfficerMr. Christopher W. Krueger J.D., MBAChief Bus. OfficerDr. Sheila K. Gujrathi M.D.Executive ChairpersonDr. Raju S. Mohan Ph.D.Founder, Chief Executive Officer & DirectorDr. William J. Sandborn M.D., Ph.D.Pres & Chief Medical OfficerDr. Martin Douglas Auster M.D.Chief Financial Officer

NASDAQ : VTYX

Ventyx Biosciences

$14.00

At Close 4:00 PM

58.95

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Ventyx Biosciences, Inc. (VTYX) stock remained unchanged at $14.00 a share on NASDAQ. The stock opened at $14.00, fluctuating between $14.00 to $14.00 during the session.

Stock Snapshot

Prev. Close

Market Cap

Day Low

-9.4

P/E Ratio

-1.49

EPS (TTM)

-2.83

Cash Flow per Share

Open

71.75M

Number of Shares

Day High

88.62%

Free Float in %

4.13

Book Value

5.4M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 03, 2026	13.99	14.00	13.99	14.00	5.41M
Mar 02, 2026	13.97	13.99	13.97	13.98	1.87M
Feb 27, 2026	13.97	14.00	13.96	13.97	19.09M
Feb 26, 2026	13.97	13.98	13.97	13.97	698.68K
Feb 25, 2026	13.96	13.98	13.96	13.97	607.95K
Feb 24, 2026	13.95	13.97	13.95	13.96	1.1M
Feb 23, 2026	13.96	13.98	13.94	13.95	3.44M
Feb 20, 2026	13.96	13.97	13.95	13.97	3.69M
Feb 19, 2026	13.96	13.97	13.95	13.96	2.1M
Feb 18, 2026	13.96	13.97	13.95	13.96	3.91M
Feb 17, 2026	13.95	13.97	13.94	13.95	3.95M
Feb 13, 2026	13.94	13.97	13.93	13.97	2.51M
Feb 12, 2026	13.95	13.96	13.92	13.93	6.48M
Feb 11, 2026	13.95	13.96	13.94	13.94	913.72K
Feb 10, 2026	13.95	13.97	13.95	13.96	662.83K
Feb 09, 2026	13.93	13.96	13.93	13.95	973.91K
Feb 06, 2026	13.92	13.96	13.91	13.96	1.46M
Feb 05, 2026	13.93	13.95	13.89	13.94	2.26M
Feb 04, 2026	13.97	13.97	13.90	13.91	4.89M
Feb 03, 2026	13.96	13.97	13.95	13.95	1.93M

Contact Details

San Diego, CA 92024

United States

https://www.ventyxbio.com 760 593 4832

About Company

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Stock Peers

REGN

-14.93-1.97%

Regeneron Pharmaceuticals, Inc.$744.12 ARGX

-21.26-3.01%

argenx SE$684.77 UTHR

-9.67-1.79%

United Therapeutics Corporation$530.35 VRTX

-10.9-2.36%

Vertex Pharmaceuticals Incorporated$451.59 MDGL

-1.18-0.27%

Madrigal Pharmaceuticals, Inc.$442.00 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-5.62-1.75%

Alnylam Pharmaceuticals, Inc.$314.80 PRAX

-14.59-4.81%

Praxis Precision Medicines, Inc.$288.79 KRYS

-5.5-2.15%

Krystal Biotech, Inc.$250.83 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

The stock is currently mid-range between its 52-week high and low $0.78 and $25.00. With a market capitalization of about $1.00 billion, Ventyx Biosciences, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.27). Key stats such as the average daily volume over the past year has been around 3.81 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Ventyx Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sheila K. Gujrathi, the company employs approximately 81 people and listed since October 21, 2021. Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 0.12%, SMA50 13.01%, SMA200 127.2%). The stock’s 14-day RSI is 71.66 (overbought), while the ATR of 0.2 points to moderate volatility. The stock remains hovering near 52-week lows, trading -44.12% below its high and over 1684.16% above its low.

Valuation Metrics

Ventyx Biosciences, Inc. trades at a P/E ratio of -9.36, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.22 trading at moderately above to book value. The P/FCF stands at -11.43, also below market averages.

Dividend & Fair Value

Ventyx Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.24. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Ventyx Biosciences, Inc. generated EPS of -$1.50 over the past year. Five-year average earnings growth is -87.13%. Wall Street analysts project EPS growth of 6.9% annually over the next five years. The latest quarter delivered EPS of -$0.32. The next quarter is forecast at -$0.37. Next year's EPS is expected at $11.93. Analyst sentiment is neutral. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $11.00. The high target offers 42.86% upside. The low target suggests -21.43% downside. The mean target is $15.55. This offers 11.07% upside. Ventyx Biosciences, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by -28.89%. The prior quarter beat by -15.56%. Over the last six quarters, Apple has recorded several small beats. These include -21.05% in August 08, 2024.

Shareholding & Insider Activity

Ventyx Biosciences, Inc. has 71.31 million shares outstanding. The public float is 53.56 million shares, elevated short interest at 6.71% of float. This equals 4.50 million shares. The short ratio is 6.43 days. Institutional investors hold 71.53% of the float. Insiders own 4.24%. Subramaniam Somu holds 8.44 million shares, NSV Partners III LP has 8.44 million shares and Mohan Raju has 2.37 million shares. Over the past six months, insider transactions show net selling. They sold 60.02 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Ventyx Biosciences has not generated any revenue. Returns are negative, with ROA at -69.49% and ROE at -79.11%.
On valuation metrics, Ventyx Biosciences trades at a P/E of -9.36, P/S of 0.00 and P/B of 5.22. The current ratio is 17.86 and quick ratio is 17.86. Debt-to-equity is 0.05, supported by a cash flow-to-debt ratio of -8.75.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Ventyx Biosciences posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $941.00K (margin 0.00%). Operating income was - $205.49M (margin 0.0%). Net income was- $192.96M (EPS - $3.30).
The company ended the quarter with $252.22M in cash and short-term investments, a total debt of $12.51M, and net debt of - $39.07M. Total assets were $277.69M, with equity of $243.92M. Financials further reflected weakness, with operating cash flow of - $166.52M, free cash flow of - $167.04M, and capital expenditures of - $514.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Ventyx Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.07%, with price expected at $14.01 by March 17, 2026, within a range of $13.34 to $14.63 3-Month Outlook: Projected rise of 59.29%, reaching $22.30 by June 01, 2026, with a range of $22.15 to $22.44. 1-Year Outlook: Projected gain of 194.43%, with price at $41.22 by March 03, 2027, within a range of $43.73 to $44.91.

Key Takeaways

Ventyx Biosciences, Inc. (NASDAQ:VTYX) shares are up 53.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Ventyx Biosciences, Inc. trading at a premium to the broader market with a P/E of -9.36. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $36.20, suggesting 158.57% upside. Our AI forecast model points to short-term strength (0.07% over two weeks), a medium-term rise (59.29% over three months), and a longer-term gain (194.43% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Ventyx Biosciences, Inc. (VTYX) stock price?

Ventyx Biosciences, Inc. (NASDAQ: VTYX) stock price is $14.00 in the last trading session. During the trading session, VTYX stock reached the peak price of $14.00 while $14.00 was the lowest point it dropped to. The percentage change in VTYX stock occurred in the recent session was 0% while the dollar amount for the price change in VTYX stock was $0.00.

VTYX's industry and sector of operation?

The NASDAQ listed VTYX is part of Biotechnology industry that operates in the broader Healthcare sector. Ventyx Biosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of VTYX?

Dr. John M. Nuss Ph.D.
Chief Scientific Officer
Prof. William J. Sandborn M.D., Ph.D.
Pres & Chief Medical Officer
Mr. Christopher W. Krueger J.D., MBA
Chief Bus. Officer
Dr. Sheila K. Gujrathi M.D.
Executive Chairperson
Dr. Raju S. Mohan Ph.D.
Founder, Chief Executive Officer & Director
Dr. William J. Sandborn M.D., Ph.D.
Pres & Chief Medical Officer
Dr. Martin Douglas Auster M.D.
Chief Financial Officer

How VTYX did perform over past 52-week?

VTYX's closing price is 1,687.99% higher than its 52-week low of $0.78 where as its distance from 52-week high of $25.00 is -44%.

How many employees does VTYX have?

Number of VTYX employees currently stands at 81.

Link for VTYX official website?

Official Website of VTYX is: https://www.ventyxbio.com

How do I contact VTYX?

VTYX could be contacted at phone 760 593 4832 and can also be accessed through its website. VTYX operates from 662 Encinitas Boulevard, San Diego, CA 92024, United States.

How many shares of VTYX are traded daily?

VTYX stock volume for the day was 5.4M shares. The average number of VTYX shares traded daily for last 3 months was 3.81M.

What is the market cap of VTYX currently?

The market value of VTYX currently stands at $1.00B with its latest stock price at $14.00 and 71.75M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	81
Beta	1.27
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

VTYX Company Profile and Key Details

Ventyx Biosciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics